Mammospheres of letrozole-resistant breast cancer cells enhance breast cancer aggressiveness

  • Authors:
    • Jankiben R. Patel
    • Karen M. Gallegos
    • Rashidra R. Walker
    • A. Michael Davidson
    • Ian Davenport
    • Syreeta L. Tilghman
  • View Affiliations

  • Published online on: June 28, 2021     https://doi.org/10.3892/ol.2021.12881
  • Article Number: 620
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Aromatase inhibitors (AIs), such as letrozole, are considered as first‑line treatment for estrogen receptor‑positive breast cancer in postmenopausal women. Despite the successful use of letrozole, resistance to therapy, tumor relapse and metastasis remain principal causes of patient mortality. Although there is no therapy currently available for AI‑resistant breast cancer, previous reports have demonstrated that AI resistance is associated with hormone independence, increased growth factor signaling, enhanced cellular motility and epithelial to mesenchymal transition (EMT). This suggests a convergence of EMT and cancer stem cells (CSCs) in endocrine resistance. The present study evaluated the contribution of mammospheres in letrozole‑resistant breast cancer by characterizing mammospheres and their potential impact on cellular motility. Ovariectomized immunocompromised female mice were inoculated in the mammary fat pad with either letrozole‑resistant MCF‑7 cells (LTLT‑Ca) or letrozole‑sensitive MCF‑7 cells (AC‑1). Subsequently, intratumoral CSC marker expression was assessed by immunohistochemistry. The results indicated that LTLT‑Ca tumors were CD44+/CD24+, while AC‑1 tumors presented low CD44/CD24 expression. Since mammosphere formation depends on CSCs, both cell lines were cultured either adherently (2D) or as mammospheres (3D) to assess the CD44/CD24 protein expression profile. When 3D culturing both cell lines, higher expression levels of CD44 and CD24 were observed when compared with their adherent counterparts, with the most robust change observed in the LTLT‑Ca cell line. To quantitate the breast cancer stem cell activity, mammosphere formation assays were performed, and the LTLT‑Ca cells formed mammospheres at a 3.4‑fold higher index compared with AC‑1 cells. Additionally, targeted gene expression arrays were conducted to compare the LTLT‑Ca 3D and 2D cells, revealing that LTLT‑Ca 3D cells displayed decreased expression levels of genes involved in cell adhesion and tumor suppression (e. g., E‑cadherin, caveolin 1 and β‑catenin). To validate this finding, wound healing assays were performed, and LTLT‑Ca mammospheres exhibited a 70% wound closure, whereas AC‑1 mammospheres exhibited a 39% wound closure. Collectively, the present findings demonstrated a strong association between AI‑resistant mammospheres and an increased propensity for migration, which may be indicative of a poor prognosis.
View Figures
View References

Related Articles

Journal Cover

August-2021
Volume 22 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Patel JR, Gallegos KM, Walker RR, Davidson AM, Davenport I and Tilghman SL: Mammospheres of letrozole-resistant breast cancer cells enhance breast cancer aggressiveness. Oncol Lett 22: 620, 2021
APA
Patel, J.R., Gallegos, K.M., Walker, R.R., Davidson, A.M., Davenport, I., & Tilghman, S.L. (2021). Mammospheres of letrozole-resistant breast cancer cells enhance breast cancer aggressiveness. Oncology Letters, 22, 620. https://doi.org/10.3892/ol.2021.12881
MLA
Patel, J. R., Gallegos, K. M., Walker, R. R., Davidson, A. M., Davenport, I., Tilghman, S. L."Mammospheres of letrozole-resistant breast cancer cells enhance breast cancer aggressiveness". Oncology Letters 22.2 (2021): 620.
Chicago
Patel, J. R., Gallegos, K. M., Walker, R. R., Davidson, A. M., Davenport, I., Tilghman, S. L."Mammospheres of letrozole-resistant breast cancer cells enhance breast cancer aggressiveness". Oncology Letters 22, no. 2 (2021): 620. https://doi.org/10.3892/ol.2021.12881